MedDRA preferred term

Incorrect product administration duration: adverse event reports recording this term

20,027 reports to FDA record it, 2010–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

20,027
reports recording the term: 0.1% of all reports; 1,452
reports, 12 months to June 2026: 1,732 in the 12 months before; 29.3%
marked serious by the reporter: 57.4% across all reports; 2%
record death among outcomes, as reported: 9.1% across all reports

"Incorrect product administration duration" is a MedDRA preferred term recorded in 20,027 adverse event reports received by FDA, 0.1% of the database, from November 2010 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,452 reports recorded it in the 12 months to June 2026, down 16% from 1,732 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 29.3% are marked serious, 2% include death among the outcomes and 8.9% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Nexplanon, Polyethylene glycol 3350 and MiraLAX. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Nexplanon	Progestin	3,509	8%
Polyethylene glycol 3350	Osmotic laxative	1,253	21.8%
MiraLAX	Osmotic laxative	1,053	2.8%
Paxlovid	—	734	1.4%
Abreva	Non-Standardized chemical allergen	611	4.5%
Loperamide hydrochloride	Opioid agonist	443	8.6%
Prevacid 24 HR	Proton pump inhibitor	422	2.1%
Humalog	Insulin analog	358	0.5%
Aleve	Nonsteroidal anti-inflammatory drug	340	0.7%
Implanon	—	325	3.5%
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	308	0.6%
Fosamax	Bisphosphonate	284	0.8%
Dupixent	Interleukin-4 receptor alpha antagonist	244	0.1%
Acetaminophen	Nonsteroidal anti-inflammatory drug	218	0.3%
Dexilant	Proton pump inhibitor	206	0.9%
Nuvaring	Estrogen	206	1.1%
Forteo	Parathyroid hormone analog	205	0.2%
Insulin glargine	Insulin analog	203	0.7%
Omeprazole	Proton pump inhibitor	179	0.3%
Etonogestrel	Progestin	168	8%
Hetlioz	Melatonin receptor agonist	165	2.9%
Alendronate sodium	Bisphosphonate	159	0.9%
Mucinex	Expectorant	153	3%
Lansoprazole	Proton pump inhibitor	146	0.5%
Infliximab	Tumor necrosis factor blocker	142	0.3%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Progestin	3,685	1.3%	0%
Osmotic laxative	2,340	1.8%	0%
Nonsteroidal anti-inflammatory drug	1,484	0.3%	0%
Proton pump inhibitor	1,469	0.3%	0.1%
Corticosteroid	855	0.1%	0%
Opioid agonist	844	0.1%	0%
Tumor necrosis factor blocker	823	0.1%	0.1%
Insulin analog	778	0.3%	0%
Non-Standardized chemical allergen	611	3.9%	0%
Expectorant	605	1.2%	2.8%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.3%61

2 to 111%191

12 to 170.9%189

18 to 4414.8%2,959

45 to 6412.1%2,414

65 to 7410.1%2,026

75 and over13.1%2,618

Age not given47.8%9,569

Patient sex

Female63.5%12,715

Male25.3%5,060

Not given11.2%2,252

Grey bar: all 20,646,523 reports in the database. 83.7% of these reports give the United States as the country.

Questions about "Incorrect product administration duration"

What does "Incorrect product administration duration" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record incorrect product administration duration?

20,027 reports through June 2026 (0.1% of all reports), 1,452 of them in the latest 12 months.

Which drugs appear most often in these reports?

Nexplanon (3,509), Polyethylene glycol 3350 (1,253), MiraLAX (1,053), Paxlovid (734) and Abreva (611). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.